A study testing nivolumab with relatlimab for melanoma that has spread to the brain
Official title: Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study is testing whether two immune drugs, given together, can help control melanoma that has spread to the brain.
Read our full plain-language summary
What the trial team says
To learn if giving nivolumab in combination with relatlimab can help to control melanoma that has spread to the brain (melanoma with brain metastases). The safety and side effects of the study drug combination will also be studied.
Key facts
- Registry number
- NCT05704647
- Stage of testing
- Phase 2
- Conditions studied
- Melanoma (Skin)
Where it is running
This trial lists 1 site.
-
Texas
- M D Anderson Cancer Center (Houston)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.